Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
Standard
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. / Cortes, J; Kim, D-W; Raffoux, E; Martinelli, G; Ritchie, E; Roy, L; Coutre, S; Corm, S; Hamerschlak, N; Tang, J-L; Hochhaus, A; Khoury, H J; Brümmendorf, Tim; Michallet, M; Rege-Cambrin, G; Gambacorti-Passerini, C; Radich, J P; Ernst, T; Zhu, C; Van Tornout, J M A; Talpaz, M.
In: LEUKEMIA, Vol. 22, No. 12, 12, 2008, p. 2176-2183.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
AU - Cortes, J
AU - Kim, D-W
AU - Raffoux, E
AU - Martinelli, G
AU - Ritchie, E
AU - Roy, L
AU - Coutre, S
AU - Corm, S
AU - Hamerschlak, N
AU - Tang, J-L
AU - Hochhaus, A
AU - Khoury, H J
AU - Brümmendorf, Tim
AU - Michallet, M
AU - Rege-Cambrin, G
AU - Gambacorti-Passerini, C
AU - Radich, J P
AU - Ernst, T
AU - Zhu, C
AU - Van Tornout, J M A
AU - Talpaz, M
PY - 2008
Y1 - 2008
N2 - Dasatinib is an inhibitor of BCR-ABL and SRC-family kinases for patients with imatinib-resistant or -intolerant chronic myelogenous leukemia (CML). In this international phase II trial, dasatinib was administered orally (70 mg twice daily) to patients with myeloid blast phase (MBP, n=109) or lymphoid blast phase (LBP, n=48) CML. After a minimum follow-up of 12 months (range 0.03-20.7 months), major hematologic responses were induced in 34% (MBP-CML) and 35% (LBP-CML) of patients. Major cytogenetic responses were attained in 33% (MBP-CML) and 52% (LBP-CML) of patients and complete cytogenetic responses were attained in 26 and 46%, respectively. Median progression-free survival was 6.7 (MBP-CML) and 3.0 (LBP-CML) months. Median overall survival was 11.8 (MBP-CML) and 5.3 (LBP-CML) months. Overall, dasatinib had acceptable tolerability. Fluid retention events were more frequent in the MBP-CML than the LBP-CML cohort: pleural effusion occurred in 36 and 13% (all grades) and 15 and 6% (grades 3/4), respectively. Other non-hematologic side effects were primarily grade 1/2; grade 3/4 events were recorded in
AB - Dasatinib is an inhibitor of BCR-ABL and SRC-family kinases for patients with imatinib-resistant or -intolerant chronic myelogenous leukemia (CML). In this international phase II trial, dasatinib was administered orally (70 mg twice daily) to patients with myeloid blast phase (MBP, n=109) or lymphoid blast phase (LBP, n=48) CML. After a minimum follow-up of 12 months (range 0.03-20.7 months), major hematologic responses were induced in 34% (MBP-CML) and 35% (LBP-CML) of patients. Major cytogenetic responses were attained in 33% (MBP-CML) and 52% (LBP-CML) of patients and complete cytogenetic responses were attained in 26 and 46%, respectively. Median progression-free survival was 6.7 (MBP-CML) and 3.0 (LBP-CML) months. Median overall survival was 11.8 (MBP-CML) and 5.3 (LBP-CML) months. Overall, dasatinib had acceptable tolerability. Fluid retention events were more frequent in the MBP-CML than the LBP-CML cohort: pleural effusion occurred in 36 and 13% (all grades) and 15 and 6% (grades 3/4), respectively. Other non-hematologic side effects were primarily grade 1/2; grade 3/4 events were recorded in
M3 - SCORING: Zeitschriftenaufsatz
VL - 22
SP - 2176
EP - 2183
JO - LEUKEMIA
JF - LEUKEMIA
SN - 0887-6924
IS - 12
M1 - 12
ER -
